Micromet to Report Third Quarter 2011 Financial Results on November 8

ROCKVILLE, Md.--(BUSINESS WIRE)-- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that it will host a conference call and audio webcast to review its third quarter 2011 financial results on Tuesday, November 8, 2011, at 8:30 AM ET.

To participate in the conference call, please dial 866-788-0540 (domestic) or 857-350-1678 (international) and reference the access code 68459017. The presentation will be available via webcast in the Investors and Media section of the Micromet website at www.micromet.com.

A replay of the call will be available from 11:30 AM ET on November 8, 2011 until midnight ET on November 15, 2011. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 24160187. The archived webcast will be available for 30 days at www.micromet.com.

About Micromet, Inc.

Micromet is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. The Company is advancing a robust pipeline of novel therapeutics based on its proprietary BiTE® technology. The Company's lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Amgen, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Nycomed and Sanofi. For additional information, please visit www.micromet.com



CONTACT:

Micromet, Inc.
Jennifer Neiman
Director, Corporate Communications
240-235-0246
[email protected]

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Professional Services  Finance  Research  Science

MEDIA:

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.